Merged with Concentra Biosciences in Sep 2025
IGMS - IGM Biosciences, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Mountain View,
United States
Type: Equity
IGMS price evolution
IGMS
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $67.26 | $79.5 | $113.11 | |
| Short term investments | $189.41 | $214.59 | $225.16 | |
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $229.63 | $266.02 | $302.75 | $347.6 |
| Long term investments | ||||
| Property, plant & equipment | $73.74 | $69.05 | $71.77 | $74 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $70.48 | $73.38 | $75.81 | |
| Total investments | $189.41 | $214.59 | $225.16 | |
| Total assets | $304.51 | $336.5 | $376.13 | $423.41 |
| Current liabilities | ||||
| Accounts payable | $3.54 | $3.26 | $4 | $1.33 |
| Deferred revenue | $145.05 | $146.3 | $146.8 | |
| Short long term debt | $5.94 | $6.63 | $5.83 | |
| Total current liabilities | $43.96 | $37.66 | $37.93 | $42.48 |
| Long term debt | $33.44 | $34.3 | $34.67 | |
| Total noncurrent liabilities | $176.49 | $176.95 | $177.7 | |
| Total debt | $39.37 | $40.93 | $40.51 | |
| Total liabilities | $225.56 | $214.14 | $214.88 | $220.18 |
| Shareholders' equity | ||||
| Retained earnings | -$980.39 | -$918.96 | -$871.06 | -$821.24 |
| Other shareholder equity | -$0.2 | -$0.13 | $0.15 | |
| Total shareholder equity | $122.36 | $161.25 | $203.23 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $113.11 | $121.92 | $134.03 | $241.08 |
| Short term investments | $225.16 | $305.93 | $96.21 | $125.19 |
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $347.6 | $438.42 | $240.75 | $373.27 |
| Long term investments | ||||
| Property, plant & equipment | $74 | $73.08 | $56.34 | $34.81 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $75.81 | $75.08 | $57.38 | $35.36 |
| Total investments | $225.16 | $305.93 | $96.21 | $125.19 |
| Total assets | $423.41 | $513.5 | $298.13 | $408.63 |
| Current liabilities | ||||
| Accounts payable | $1.33 | $2.51 | $5.58 | $7.92 |
| Deferred revenue | $146.8 | $148.93 | ||
| Short long term debt | $5.83 | $5.82 | $3.32 | $2.67 |
| Total current liabilities | $42.48 | $44.69 | $27.78 | $17.24 |
| Long term debt | $34.67 | $35.36 | $25.44 | $9.58 |
| Total noncurrent liabilities | $177.7 | $181.55 | $25.44 | $9.58 |
| Total debt | $40.51 | $41.17 | $28.76 | $12.24 |
| Total liabilities | $220.18 | $226.24 | $53.22 | $26.82 |
| Shareholders' equity | ||||
| Retained earnings | -$821.24 | -$574.83 | -$353.72 | -$188.56 |
| Other shareholder equity | $0.15 | -$0.7 | -$0.07 | $0.03 |
| Total shareholder equity | $203.23 | $287.26 | $244.91 | $381.81 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $0.52 | $1.25 | $0.5 | $0.65 |
| Cost of revenue | ||||
| Gross Profit | $1.25 | $0.5 | $0.65 | |
| Operating activities | ||||
| Research & development | $41.96 | $43.81 | $54.19 | |
| Selling, general & administrative | $10.65 | $10.54 | $11.58 | |
| Total operating expenses | $50.91 | $52.61 | $54.35 | $65.77 |
| Operating income | -$51.36 | -$53.86 | -$65.12 | |
| Income from continuing operations | ||||
| EBIT | -$47.9 | -$49.82 | -$60.45 | |
| Income tax expense | $0.24 | |||
| Interest expense | $2.96 | |||
| Net income | ||||
| Net income | -$61.43 | -$47.9 | -$49.82 | -$60.7 |
| Income (for common shares) | -$47.9 | -$49.82 | -$60.7 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $2.13 | $1.07 | ||
| Cost of revenue | ||||
| Gross Profit | $2.13 | $1.07 | ||
| Operating activities | ||||
| Research & development | $215.52 | $179.29 | $127.03 | $65.03 |
| Selling, general & administrative | $50.07 | $49.74 | $38.3 | $18.25 |
| Total operating expenses | $265.59 | $229.03 | $165.32 | $83.28 |
| Operating income | -$263.46 | -$227.96 | -$165.32 | -$83.28 |
| Income from continuing operations | ||||
| EBIT | -$245.74 | -$221.1 | -$165.16 | -$81.36 |
| Income tax expense | $0.68 | |||
| Interest expense | ||||
| Net income | ||||
| Net income | -$246.42 | -$221.1 | -$165.16 | -$81.36 |
| Income (for common shares) | -$246.42 | -$221.1 | -$165.16 | -$81.36 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$47.9 | -$49.82 | -$60.7 | |
| Operating activities | ||||
| Depreciation | $3.71 | $3.59 | $3.56 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $8.43 | $7.92 | $9.24 | |
| Total cash flows from operations | -$37.37 | -$42.42 | -$48.01 | |
| Investing activities | ||||
| Capital expenditures | -$1.18 | -$2.48 | -$1.45 | |
| Investments | $25.71 | $11.13 | -$13.24 | |
| Total cash flows from investing | $46.16 | $24.52 | $8.65 | -$14.69 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.65 | $0.19 | $0.4 | |
| Net borrowings | ||||
| Total cash flows from financing | $1.97 | $0.61 | $0.15 | $0.4 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$70.05 | -$12.23 | -$33.61 | -$62.3 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$246.42 | -$221.1 | -$165.16 | -$81.36 |
| Operating activities | ||||
| Depreciation | $13.69 | $10.6 | $7.72 | $3.58 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $46.55 | $44.71 | $25.87 | $8.45 |
| Total cash flows from operations | -$192.23 | -$5.85 | -$124.34 | -$67.3 |
| Investing activities | ||||
| Capital expenditures | -$12.38 | -$10.21 | -$13.24 | -$17.5 |
| Investments | $80.74 | -$215.44 | $28.06 | $75.21 |
| Total cash flows from investing | $68.36 | -$225.64 | $14.82 | $57.71 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $115.07 | $219.38 | $4.03 | $216.51 |
| Net borrowings | ||||
| Total cash flows from financing | $115.07 | $219.38 | $2.48 | $214.78 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$8.81 | -$12.12 | -$107.05 | $205.19 |
News
Fundamentals
| Market cap | $75.50M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 59.45M |
| Revenue | $2.92M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$219.84M |
| Revenue Q/Q | 1.38% |
| Revenue Y/Y | 57.64% |
| P/E ratio | -0.34 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 25.87 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$3.70 |
|---|---|
| ROA | -61.04% |
| ROE | N/A |
| Debt/Equity | 1.08 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 5.22 |
| Quick ratio | N/A |